Literature DB >> 20083264

Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria.

Robert S Svatek1, Mark B Fisher, Surena F Matin, Ashish M Kamat, H Barton Grossman, Graciela M Nogueras-González, Diana L Urbauer, Kathleen A Kennedy, Colin P Dinney.   

Abstract

PURPOSE: Adverse event reporting is poorly classified and nonstandardized in the urological literature. We report adverse event data and associated risk factors using standardized reporting methods and Common Terminology Criteria for Adverse Events, version 3.0 to minimize interpretation bias and allow reliable comparisons with other populations.
MATERIALS AND METHODS: We retrospectively reviewed consecutive radical cystectomies done for urothelial bladder carcinoma at our institution between January 2004 and September 2006. Adverse events within 90 days postoperatively were recorded. We explored the association of important risk factors with the overall complication rate and specific complications.
RESULTS: A total of 283 patients were included in the study. Complete 90-day followup data were available on 90% of patients. Median age was 70 years (IQR 62-75). Median body mass index was 26.8 kg/m(2) (IQR 24.4-31.0). At least 1 adverse event was observed in 152 patients (54.0%) and a grade 3-4 adverse event was observed in 40.3%. The most common grade 4 adverse events were myocardial infarction in 3.5% of cases, septic shock in 2.8% and pulmonary embolism in 1.8%. No patient died during followup. An association between body mass index, and any and major adverse events was found after adjusting for confounding variables.
CONCLUSIONS: More than 50% of patients experience an adverse event after radical cystectomy and 40% are major. Body mass index is independently associated with adverse events in these patients. These findings are important for individualized risk assessment, patient counseling and uniform assessment of quality care. 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20083264     DOI: 10.1016/j.juro.2009.11.038

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  21 in total

1.  Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer.

Authors:  Robert S Svatek; Niannian Ji; Essel de Leon; Neelam Z Mukherjee; Aashish Kabra; Vincent Hurez; Marlo Nicolas; Joel E Michalek; Martin Javors; Karen Wheeler; Z Dave Sharp; Carolina B Livi; Zhen-Ju Shu; David Henkes; Tyler J Curiel
Journal:  Cancer Immunol Res       Date:  2018-12-18       Impact factor: 11.151

2.  Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentafecta.

Authors:  Atiqullah Aziz; Michael Gierth; Michael Rink; Marianne Schmid; Felix K Chun; Roland Dahlem; Florian Roghmann; Rein-Jüri Palisaar; Joachim Noldus; Jörg Ellinger; Stefan C Müller; Armin Pycha; Thomas Martini; Christian Bolenz; Rudolf Moritz; Edwin Herrmann; Bastian Keck; Bernd Wullich; Roman Mayr; Hans-Martin Fritsche; Maximilian Burger; Patrick J Bastian; Christian Seitz; Sabine Brookman-May; Evanguelos Xylinas; Shahrokh F Shariat; Margit Fisch; Matthias May
Journal:  World J Urol       Date:  2015-05-07       Impact factor: 4.226

3.  Long-term changes in renal function outcomes following radical cystectomy and urinary diversion.

Authors:  Masatomo Nishikawa; Hideaki Miyake; Masuo Yamashita; Taka-aki Inoue; Masato Fujisawa
Journal:  Int J Clin Oncol       Date:  2014-01-21       Impact factor: 3.402

Review 4.  Perioperative outcomes and safety of robotic vs open cystectomy: a systematic review and meta-analysis of 12,640 cases.

Authors:  Keiran D Clement; Emily Pearce; Ahmed H Gabr; Bhavan P Rai; Abdulla Al-Ansari; Omar M Aboumarzouk
Journal:  World J Urol       Date:  2020-07-30       Impact factor: 4.226

Review 5.  Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review.

Authors:  Janie Allaire; Tal Ben-Zvi; Benoît Lamarche; Karine Robitaille; Yves Fradet; Louis Lacombe; Vincent Fradet
Journal:  Can Urol Assoc J       Date:  2017-11-01       Impact factor: 1.862

6.  Complications within 90 days after radical cystectomy for bladder cancer: results of a multicenter prospective study in Japan.

Authors:  Megumi Hirobe; Toshiaki Tanaka; Tetsuya Shindo; Koji Ichihara; Hiroshi Hotta; Atsushi Takahashi; Ryuichi Kato; Masahiro Yanase; Masanori Matsukawa; Naoki Itoh; Yasuharu Kunishima; Keisuke Taguchi; Hiroki Horita; Naoya Masumori
Journal:  Int J Clin Oncol       Date:  2018-02-13       Impact factor: 3.402

7.  Chemoradiation Vs Radical Cystectomy for Muscle-invasive Bladder Cancer: A Propensity Score-weighted Comparative Analysis Using the National Cancer Database.

Authors:  Dharam Kaushik; Hanzhang Wang; Joel Michalek; Michael A Liss; Qianqian Liu; Richa Priya Jha; Robert S Svatek; Ahmed M Mansour
Journal:  Urology       Date:  2019-08-08       Impact factor: 2.649

8.  Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder.

Authors:  Michael S Cookson; Sam S Chang; Christine Lihou; Thomas Li; Samira Q Harper; Zhihui Lang; Ronald F Tutrone
Journal:  Ther Adv Urol       Date:  2014-10

9.  Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process.

Authors:  Jo-An Seah; Normand Blais; Scott North; Yasmin Rahim; Dean Ruether; Peter C Black; Alexandre R Zlotta; Lori Wood; Srikala S Sridhar
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

Review 10.  Patient Psoas Muscle Mass as a Predictor of Complications and Survival After Radical Cystectomy.

Authors:  Hamed Ahmadi; James E Montie; Alon Z Weizer; Todd Morgan; Jeffrey S Montgomery; Cheryl T Lee
Journal:  Curr Urol Rep       Date:  2015-11       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.